Acutaas Chemicals Ltd. (ACUTAAS) fundamentals
Acutaas Chemicals Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ACUTAAS (ISIN INE00FF01025). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Acutaas Chemicals Ltd. does
Acutaas Chemicals Limited, formerly Ami Organics Limited, is a manufacturer of pharma intermediates and specialty chemicals. It is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. It manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. It has developed and commercialized over 520 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE across select high-growth high margin chronic therapeutic areas.
Valuation and market data
| Last close | ₹3348.80 |
|---|---|
| Market capitalisation | ₹27,428 crore |
| Enterprise value | ₹27,255 crore |
| P/E (TTM) | 76.97 |
| Price to book | 16.03 |
| Price to sales (TTM) | 11.50 |
| Book value per share | ₹208.87 |
| Dividend yield | 7.47% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Sep 14 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,381 crore | ₹483 crore | ₹356 crore | 43.51 |
| Mar 2025 | ₹1,024 crore | ₹216 crore | ₹160 crore | 19.81 |
| Mar 2024 | ₹725 crore | ₹82 crore | ₹49 crore | 11.67 |
| Mar 2023 | ₹621 crore | ₹112 crore | ₹83 crore | 22.86 |
| Mar 2022 | ₹523 crore | ₹91 crore | ₹72 crore | 21.03 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 32.7% |
|---|---|
| Foreign institutions (FII) | 22.6% |
| Mutual funds | 14.4% |
| Other domestic institutions | 5.0% |
| Retail and others | 25.3% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.